Literature DB >> 12051461

Disability and treatment patterns of multiple sclerosis patients in United States: a comparison of veterans and nonveterans.

Timothy L Vollmer1, Olympia Hadjimichael, Jana Preiningerova, Weijia Ni, Joan Buenconsejo.   

Abstract

The Veterans Health Administration (VHA) is the largest integrated healthcare system in the world and provides care to approximately 20,000 multiple sclerosis (MS) patients. Here, we report that these MS patients are disproportionately more likely to be older, male, unemployed, and disabled with lower levels of education and financial resources when compared to veterans not receiving care within the VHA or to nonveteran MS patients. When comparing the VHA MS patients to a cohort of nonveteran MS patients matched for age, sex, and disability, we found that veterans receiving care within the VHA were equally likely to have received care from a neurologist and more likely to have received care from rehabilitation specialists and primary care physicians than nonveterans. Similarly, veterans in the VHA were more likely to receive therapy with certain symptomatic medications but were less likely to be treated with disease-modifying agents for MS (DMAMS) than nonveterans. When treated with DMAMS, they are more likely to be treated with Avonex and significantly less likely to receive treatment with Copaxone or Novantrone.

Entities:  

Mesh:

Year:  2002        PMID: 12051461

Source DB:  PubMed          Journal:  J Rehabil Res Dev        ISSN: 0748-7711


  5 in total

Review 1.  Evidence Review-Social Determinants of Health for Veterans.

Authors:  Wei Duan-Porter; Brian C Martinson; Nancy Greer; Brent C Taylor; Kristen Ullman; Lauren McKenzie; Christina Rosebush; Roderick MacDonald; Samuel Falde; Timothy J Wilt
Journal:  J Gen Intern Med       Date:  2018-07-20       Impact factor: 5.128

2.  Employment in multiple sclerosis. Exiting and re-entering the work force.

Authors:  Laura J Julian; Lea Vella; Tim Vollmer; Olympia Hadjimichael; David C Mohr
Journal:  J Neurol       Date:  2008-07-17       Impact factor: 4.849

3.  Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate.

Authors:  Spencer Moore; Anna J Khalaj; Rhusheet Patel; JaeHee Yoon; Daniel Ichwan; Liat Hayardeny; Seema K Tiwari-Woodruff
Journal:  J Neurosci Res       Date:  2014-07-03       Impact factor: 4.164

4.  Use and cost of disease-modifying therapies by Sonya Slifka Study participants: has anything really changed since 2000 and 2009?

Authors:  Sarah L Minden; R Philip Kinkel; Helene T Machado; Jonathan S Levin; Meredith B Rosenthal; Lisa I Iezzoni
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-02-20

5.  Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey.

Authors:  Olympia Hadjimichael; Timothy Vollmer; MerriKay Oleen-Burkey
Journal:  Health Qual Life Outcomes       Date:  2008-11-14       Impact factor: 3.186

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.